Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers continue to fight Medicare price negotiations under the Biden-era Inflation | Following a string of defeats for the industry in challenging the Inflation Reduction Act, Hail Mary efforts from a handful of companies to have their criticisms heard by the United States’ High Court have fallen flat.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The…

Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout

With questions already swirling about the actual affordability impact of t | With questions already swirling about the actual…

The rejection may make the pharma firms remaining lawsuits more difficult.

Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations

The Supreme Court has rejected appeals from pharmaceutical companies that object to negotiating Medicare drug prices with the…

The Supreme Court won't take up IRA cases

Supreme Court rejects challenge to Medicare drug price negotiation

Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations

Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations with government

Supreme Court rejects Big Pharma appeals challenging negotiated drug prices in Medicare | CNN Politics

Pharma companies want to block Medicare drug discounts. Supreme Court weighs in

CMS to withhold $1.3B in Medicaid funds from California, puts state officials on notice about fraud

OIG: Jury still out on impacts of vertical consolidation in Part D

Pharmalittle: We're reading about a Supreme Court setback for pharma, TrumpRx expands and much more

A political contest in the U.K. could shake up drug pricing